In a subgroup analysis of the RE-MIND2 study, researchers found tafasitamab plus lenalidomide may be associated with improved overall survival (OS) vs selected systemic therapies for high-risk relapsed/refractory diffuse large B-cell lymphoma (DLBCL). These findings were presented at the 2022 ASCO Annual Meeting.

“Tafasitamab plus lenalidomide demonstrated efficacy in adult patients with [relapsed/refractory] DLBCL ineligible for autologous stem-cell transplant in the pivotal phase 2 study L-MIND and received accelerated approval in the United States in 2020 and conditional marketing authorization in Europe and Canada in 2021 in this setting,” explained Grzegorz Nowakowski, MD, Mayo Clinic, Rochester, MN, and colleagues.

This study, RE-MIND2, is an observational, retrospective cohort study, that aims to compare patient outcomes from L-MIND with matched patient cohorts treated with other therapies recommended by the National Comprehensive Cancer Network (NCCN) and European Society of Medical Oncology (ESMO).

The systemic therapies compared to tafasitamab and lenalidomide were pooled systemic therapies, polatuzumab vedotin plus bendamustine and rituximab, rituximab plus lenalidomide, and CD19 chimeric antigen receptor T-cell (CAR-T) therapies.The primary end point of the study was OS.

A total of 3454 patients were enrolled in the study. Of whom, 961 were treated with pooled systemic therapies, 106 with polatuzumab vedotin plus bendamustine and rituximab, 106 with rituximab plus lenalidomide, and 149 with CAR-T therapies. These patients were matched with 76, 24, 33, and 37 patients received tafasitamab and lenalidomide, respectively.

Hazard ratios (HRs) for OS favored tafasitamab and lenalidomide in most subgroups. For tafasitamab and lenalidomide vs pooled systemic therapies, the HR for OS was 0.553 (95% confidence interval [CI], 0.358 to 0.855; P = .0068). For tafasitamab and lenalidomide vs polatuzumab vedotin plus bendamustine and rituximab, the HR for OS was 0.441 (95% CI, 0.203 to 0.956; P = 0.0340). For tafasitamab and lenalidomide vs rituximab plus lenalidomide, the HR for OS was 0.435 (95% CI, 0.224 to 0.847; P = .0122). For tafasitamab and lenalidomide vs CAR-T therapies, the HR for OS was 0.953 (95% CI, 0.475 to 1.913; P = 0.8929).

“These analyses suggest that [tafasitamab and lenalidomide] may be associated with improved OS vs selected systemic therapies for certain patients with high-risk disease and may further inform physicians’ treatment choices for patients with [relapsed/refractory DLBCL,” wrote Dr Nowakowski and colleagues.

“These analyses are not powered for statistical comparison; small sample sizes in some subgroups result in wide confidence intervals (CI) and so results must be interpreted with caution,” they concluded.

Source:

Nowakowski GS, Yoon DH, Joffe E, et al. Subgroup analysis in RE-MIND2, an observational, retrospective cohort study of tafasitamab plus lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Presented at: ASCO Annual Meeting; June 3-7, 2022. Chicago, IL, and virtual. Abstract 7560.